Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Organon & Co.
Organon & Co. News
Jul 8, 2025 - globenewswire.com
ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN
Jul 8, 2025 - businesswire.com
EXTENDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Organon & Co. and Announces Opportunity for Investors with Substantial Losses to Lead the Organon Class Action Lawsuit – OGN
Organon & Co. Quantitative Score

About Organon & Co.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Organon & Co. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Organon & Co. Financials
Table Compare
Compare OGN metrics with: | |||
---|---|---|---|
Earnings & Growth | OGN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | OGN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | OGN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | OGN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Organon & Co. Income
Organon & Co. Balance Sheet
Organon & Co. Cash Flow
Organon & Co. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Buy |
Return on Assets | Buy |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Neutral |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Organon & Co. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 0.8600 |
Payment Date | Dividend | Frequency |
---|---|---|
2025-06-12 | 0.02 | Quarterly |
2025-03-13 | 0.28 | Quarterly |
2024-12-12 | 0.28 | Quarterly |
2024-09-12 | 0.28 | Quarterly |
2024-06-13 | 0.28 | Quarterly |
Historical Market Cap
Shares Outstanding
Organon & Co. Executives
Name | Role |
---|---|
Mr. Kevin Ali | Chief Executive Officer & Director |
Mr. Matthew M. Walsh C.F.A. | Executive Vice President & Chief Financial Officer |
Mr. Joseph T. Morrissey Jr. | Executive Vice President and Head of Manufacturing & Supply |
Mr. Kirke Weaver | Executive Vice President, General Counsel & Corporate Secretary |
Dr. Juan Camilo Arjona Ferreira M.D. | Executive Vice President, Head of Research & Development and Chief Medical Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Kevin Ali | Chief Executive Officer & Director | Male | 1960 | 5.21M |
Mr. Matthew M. Walsh C.F.A. | Executive Vice President & Chief Financial Officer | Male | 1967 | 2.07M |
Mr. Joseph T. Morrissey Jr. | Executive Vice President and Head of Manufacturing & Supply | Male | 1965 | 1.75M |
Mr. Kirke Weaver | Executive Vice President, General Counsel & Corporate Secretary | Male | 1974 | 1.44M |
Dr. Juan Camilo Arjona Ferreira M.D. | Executive Vice President, Head of Research & Development and Chief Medical Officer | 1971 | 1.43M |
Organon & Co. Insider Trades
Date | 1 Jul |
Name | Sequeira Ramona |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 21890.547 |
Date | 1 Jul |
Name | Sequeira Ramona |
Role | Director |
Transaction | Disposed |
Type | |
Shares | 0 |
Date | 13 Jun |
Name | Ozuah Philip |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 23904.382 |
Date | 13 Jun |
Name | Leone Deborah R |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 23904.382 |
Date | 13 Jun |
Name | Sharp Shalini |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 23904.382 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
1 Jul | Sequeira Ramona | Director | Acquired | A-Award | 21890.547 |
1 Jul | Sequeira Ramona | Director | Disposed | 0 | |
13 Jun | Ozuah Philip | Director | Acquired | A-Award | 23904.382 |
13 Jun | Leone Deborah R | Director | Acquired | A-Award | 23904.382 |
13 Jun | Sharp Shalini | Director | Acquired | A-Award | 23904.382 |